Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Hoofddorp – page 35

1 940 clinical trials in Hoofddorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Hoofddorp at a glance
1 940
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 940 trials in Hoofddorp

Open in trial search

Inflammatory bowel disease

Recruiting

Title: Study of vedolizumab dose adjustment guided by drug level monitoring in patients with inflammatory bowel disease in remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Amsterdam UMC Stichting

Diffuse large B-cell lymphoma

Recruiting

Study of Zilovertamab Vedotin and Drug Combination for Untreated Diffuse Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Insomnia+1

Recruiting

Study on the Effects of Estradiol, Progesterone, and Online Sleep Therapy for Insomnia and Menopausal Symptoms in Perimenopausal Women

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Estradiol
  • Sponsor:Amsterdam UMC Stichting

Type IIa hyperlipidaemia

Recruiting

Study on the Safety and Effectiveness of Inclisiran in Children Aged 2 to Under 12 with Homozygous Familial Hypercholesterolemia

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Pancreatic carcinoma metastatic+1

Recruiting

Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ANOC-001
  • Sponsor:Anocca AB

Post-acute COVID-19 syndrome

Recruiting

Study on Metformin and Colchicine for Patients with Long COVID Symptoms

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Universitair Medisch Centrum Utrecht

Acquired ATTR amyloidosis

Recruiting

Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Eidos Therapeutics Inc.

Central serous chorioretinopathy

Recruiting

Study on the Effects of Prednisolone Acetate and Placebo Eye Drops for Patients with Chronic Central Serous Chorioretinopathy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dextran 70
  • Sponsor:Radboud universitair medisch centrum Stichting

Bacterial infection

Recruiting

Study on Adjusted Ciprofloxacin Dosing for Patients with Kidney Impairment and Bacterial Infections

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Amsterdam UMC Stichting

Peripheral arterial occlusive disease+1

Recruiting

Study on Low-Dose Colchicine for Patients with Peripheral Artery Disease to Reduce Cardiovascular Risks

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Neuralgia+1

Recruiting

Study on Psilocybin for Relieving Chronic Neuropathic Pain in Patients with Chemotherapy-Induced Peripheral Neuropathy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxazepam
  • Sponsor:Amsterdam UMC Stichting

Appendicitis+4

Recruiting

Study on Using Gentamicin and Clindamycin to Prevent Abscesses After Surgery for Complicated Appendicitis in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clindamycin
  • Sponsor:Amsterdam UMC Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hoofddorp

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on various cancer types including breast cancer, bladder cancer, and melanoma. Studies are evaluating novel treatment combinations and maintenance therapies for improved patient outcomes.

  • Advanced/Metastatic Breast Cancer Treatments
  • Urothelial Cancer Therapies
  • Hematologic Malignancies

Multiple trials are investigating innovative approaches for both solid tumors and blood cancers, with particular emphasis on targeted therapies.

02 Hematologic Disorders

Comprehensive studies examining treatments for various blood disorders, including chronic myeloid leukemia, myelofibrosis, and lymphomas. Focus on developing targeted therapies and combination treatments.

  • B-Cell Lymphoma Treatments
  • Myelofibrosis Therapies
  • Leukemia Management

Research aims to improve treatment outcomes and quality of life for patients with blood disorders.

03 Metabolic and Surgical Studies

Research initiatives addressing obesity management and surgical conditions like appendicitis. Studies include weight management therapies and surgical technique improvements.

  • Weight Management Interventions
  • Surgical Techniques
  • Prevention Studies

Trials focus on both therapeutic and surgical interventions for better patient outcomes.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.